The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)

Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance o...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Can Urol Assoc J
Päätekijät: Saad, Fred, Chi, Kim N., Finelli, Antonio, Hotte, Sebastien J., Izawa, Jonathan, Kapoor, Anil, Kassouf, Wassim, Loblaw, Andrew, North, Scott, Rendon, Ricardo, So, Alan, Usmani, Nawaid, Vigneault, Eric, Fleshner, Neil E.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Canadian Medical Association 2015
Aiheet:
CUA Guidelines
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4455631/
https://ncbi.nlm.nih.gov/pubmed/26085865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.2526
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia